JPWO2019162376A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019162376A5 JPWO2019162376A5 JP2020568035A JP2020568035A JPWO2019162376A5 JP WO2019162376 A5 JPWO2019162376 A5 JP WO2019162376A5 JP 2020568035 A JP2020568035 A JP 2020568035A JP 2020568035 A JP2020568035 A JP 2020568035A JP WO2019162376 A5 JPWO2019162376 A5 JP WO2019162376A5
- Authority
- JP
- Japan
- Prior art keywords
- tab
- dystonia
- bont
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108030001720 Bontoxilysin Proteins 0.000 claims 21
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 108020003175 receptors Proteins 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 18
- 208000014094 Dystonic disease Diseases 0.000 claims 13
- 208000010118 dystonia Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000005392 Spasm Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000007850 fluorescent dye Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000002537 cosmetic Substances 0.000 claims 4
- 230000001148 spastic effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 201000002904 focal dystonia Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000000946 synaptic effect Effects 0.000 claims 3
- 208000019505 Deglutition disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 2
- 206010049816 Muscle tightness Diseases 0.000 claims 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 2
- 208000004350 Strabismus Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 201000002898 anismus Diseases 0.000 claims 2
- 206010005159 blepharospasm Diseases 0.000 claims 2
- 230000000744 blepharospasm Effects 0.000 claims 2
- 201000002866 cervical dystonia Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 210000003414 extremity Anatomy 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 201000002851 oromandibular dystonia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000026451 salivation Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- 102000003137 synaptotagmin Human genes 0.000 claims 2
- 108060008004 synaptotagmin Proteins 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 210000001364 upper extremity Anatomy 0.000 claims 2
- 208000011293 voice disease Diseases 0.000 claims 2
- 241000238876 Acari Species 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 102000018389 Exopeptidases Human genes 0.000 claims 1
- 108010091443 Exopeptidases Proteins 0.000 claims 1
- 208000029728 Eyelid disease Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 208000015592 Involuntary movements Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000000632 dystonic effect Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000001755 vocal effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043984A JP2024069606A (ja) | 2018-02-26 | 2024-03-19 | ボツリヌス神経毒バイオハイブリッド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850213-8 | 2018-02-26 | ||
| SE1850213A SE542539C2 (en) | 2018-02-26 | 2018-02-26 | Chimeric botulinum neurotoxin heavy chain binding domain |
| PCT/EP2019/054310 WO2019162376A1 (en) | 2018-02-26 | 2019-02-21 | Botulinum neurotoxin biohybrid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043984A Division JP2024069606A (ja) | 2018-02-26 | 2024-03-19 | ボツリヌス神経毒バイオハイブリッド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021514674A JP2021514674A (ja) | 2021-06-17 |
| JP2021514674A5 JP2021514674A5 (https=) | 2022-03-03 |
| JPWO2019162376A5 true JPWO2019162376A5 (https=) | 2022-03-03 |
| JP7458999B2 JP7458999B2 (ja) | 2024-04-01 |
Family
ID=65576340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568035A Active JP7458999B2 (ja) | 2018-02-26 | 2019-02-21 | ボツリヌス神経毒バイオハイブリッド |
| JP2024043984A Withdrawn JP2024069606A (ja) | 2018-02-26 | 2024-03-19 | ボツリヌス神経毒バイオハイブリッド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043984A Withdrawn JP2024069606A (ja) | 2018-02-26 | 2024-03-19 | ボツリヌス神経毒バイオハイブリッド |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200407702A1 (https=) |
| EP (1) | EP3759124A1 (https=) |
| JP (2) | JP7458999B2 (https=) |
| KR (1) | KR20200127175A (https=) |
| CN (1) | CN111819189A (https=) |
| AU (2) | AU2019223130B2 (https=) |
| BR (1) | BR112020017323A2 (https=) |
| CA (1) | CA3088928A1 (https=) |
| CL (1) | CL2020002186A1 (https=) |
| IL (1) | IL276930A (https=) |
| MX (1) | MX2020008834A (https=) |
| MY (1) | MY202690A (https=) |
| PH (1) | PH12020551270A1 (https=) |
| SE (1) | SE542539C2 (https=) |
| SG (1) | SG11202006730SA (https=) |
| WO (1) | WO2019162376A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| IL272002A (en) | 2020-01-13 | 2021-07-29 | The Israel Institute Of Biological Res Iibr | Methods for identifying anti clostridial neurotoxin compounds |
| EP4093434A4 (en) * | 2020-01-21 | 2024-06-26 | Trustees of Dartmouth College | Immunologically optimized botulinum toxin light chain variants |
| CN111675754A (zh) * | 2020-05-19 | 2020-09-18 | 四川一埃科技有限公司 | 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法 |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102219837B (zh) * | 2010-05-20 | 2013-10-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 重组全长a型肉毒毒素突变体疫苗 |
| SG10201606666XA (en) * | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| US11242515B2 (en) | 2016-05-16 | 2022-02-08 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| CN109476713A (zh) | 2016-06-08 | 2019-03-15 | 儿童医学中心公司 | 工程改造的肉毒杆菌神经毒素 |
-
2018
- 2018-02-26 SE SE1850213A patent/SE542539C2/en not_active IP Right Cessation
-
2019
- 2019-02-21 SG SG11202006730SA patent/SG11202006730SA/en unknown
- 2019-02-21 US US16/975,308 patent/US20200407702A1/en not_active Abandoned
- 2019-02-21 MY MYPI2020003674A patent/MY202690A/en unknown
- 2019-02-21 EP EP19707750.6A patent/EP3759124A1/en active Pending
- 2019-02-21 CA CA3088928A patent/CA3088928A1/en active Pending
- 2019-02-21 BR BR112020017323-1A patent/BR112020017323A2/pt not_active IP Right Cessation
- 2019-02-21 MX MX2020008834A patent/MX2020008834A/es unknown
- 2019-02-21 AU AU2019223130A patent/AU2019223130B2/en not_active Expired - Fee Related
- 2019-02-21 CN CN201980015353.XA patent/CN111819189A/zh active Pending
- 2019-02-21 JP JP2020568035A patent/JP7458999B2/ja active Active
- 2019-02-21 KR KR1020207024402A patent/KR20200127175A/ko not_active Ceased
- 2019-02-21 WO PCT/EP2019/054310 patent/WO2019162376A1/en not_active Ceased
-
2020
- 2020-08-18 PH PH12020551270A patent/PH12020551270A1/en unknown
- 2020-08-25 IL IL276930A patent/IL276930A/en unknown
- 2020-08-25 CL CL2020002186A patent/CL2020002186A1/es unknown
-
2024
- 2024-03-19 JP JP2024043984A patent/JP2024069606A/ja not_active Withdrawn
- 2024-03-25 US US18/615,341 patent/US20250034540A1/en not_active Abandoned
- 2024-10-24 AU AU2024227611A patent/AU2024227611A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523015A5 (https=) | ||
| JP2019216735A5 (https=) | ||
| US20260102476A1 (en) | Use of botulinum neurotoxin in the treatment of sialorrhea | |
| JP4249802B2 (ja) | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ | |
| JP3238154B2 (ja) | 過度の発汗を軽減するためのボツリヌス毒素含有医薬組成物 | |
| JP2019528042A5 (https=) | ||
| JP2015519362A5 (https=) | ||
| JP2021514674A5 (https=) | ||
| KR20110060903A (ko) | 지속성이 변경된 클로스트리듐 신경독 | |
| FI3481852T3 (fi) | Uusi botulinum-neurotoksiini ja sen johdannaisia | |
| JP2019533430A5 (https=) | ||
| JP2015504304A (ja) | ポリ−グリシンを伴う修飾神経毒及びその使用 | |
| TWI730562B (zh) | 胜肽及具有其之組合物 | |
| JP2025118631A (ja) | ボツリヌス神経毒素効果を調節する組成物 | |
| JPWO2019162376A5 (https=) | ||
| US20120251574A1 (en) | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions | |
| US20120251575A1 (en) | Endopeptidase Treatment of Involuntary Movement Disorders | |
| RU2020131317A (ru) | Биогибрид ботулинического нейротоксина | |
| RU2019108257A (ru) | Сконструированный ботулинический нейротоксин | |
| RU2778481C2 (ru) | Улучшенное применение ботулинического нейротоксина в лечении сиалореи | |
| Korake et al. | Pharmaimportance of Botulinum Neurotoxin (Clostridium botulinum) | |
| EA046580B1 (ru) | Катионные нейротоксины |